BioCorRx Inc
OTC:BICX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BioCorRx Inc
Revenue
BioCorRx Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BioCorRx Inc
OTC:BICX
|
Revenue
$797.2k
|
CAGR 3-Years
56%
|
CAGR 5-Years
46%
|
CAGR 10-Years
-1%
|
|
|
Universal Health Services Inc
NYSE:UHS
|
Revenue
$17.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
|
Encompass Health Corp
NYSE:EHC
|
Revenue
$5.9B
|
CAGR 3-Years
11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
|
Tenet Healthcare Corp
NYSE:THC
|
Revenue
$21.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
1%
|
|
|
HCA Healthcare Inc
NYSE:HCA
|
Revenue
$75.6B
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
|
Ensign Group Inc
NASDAQ:ENSG
|
Revenue
$5.1B
|
CAGR 3-Years
19%
|
CAGR 5-Years
16%
|
CAGR 10-Years
14%
|
|
BioCorRx Inc
Glance View
BioCorRx, Inc. engages in the provision of alcoholism and opioid addiction treatment. The company is headquartered in Anaheim, California. The company went IPO on 2010-08-31. The firm's BioCorRx Recovery Program is a non-addictive, medication-assisted treatment (MAT) program for substance abuse that includes peer recovery support. The UnCraveRx Weight Loss Management Program is a medically assisted weight management program that is combined with a virtual platform application. The company is also engaged in the research and development of sustained release naltrexone products for the treatment of addiction and other possible disorders. Its products include BICX101 and BICX104. Its lead candidate, BICX101, is a sustained release, injectable naltrexone for the treatment of opioid abuse and alcoholism. The company is also developing an implantable naltrexone treatment, BICX104, a long-acting naltrexone implant that can last several months for the treatment of opioid dependence and alcohol use disorders. Its subsidiary is BioCorRx Pharmaceuticals, Inc.
See Also
What is BioCorRx Inc's Revenue?
Revenue
797.2k
USD
Based on the financial report for Dec 31, 2025, BioCorRx Inc's Revenue amounts to 797.2k USD.
What is BioCorRx Inc's Revenue growth rate?
Revenue CAGR 10Y
-1%
Over the last year, the Revenue growth was 10 253%. The average annual Revenue growth rates for BioCorRx Inc have been 56% over the past three years , 46% over the past five years , and -1% over the past ten years .
